Table 1. Characteristics of patients in the three cohorts.
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; NA, not applicable.
| FUSCC (n = 711) | DUKE (n = 641) | TCGA (n = 122) | ||
|---|---|---|---|---|
| Age [mean (SD)] | 52.6 (10.5) | 53.5 (11.4) | 53.6 (11.5) | |
| Menopause (%) | ||||
| No | 305 (42.9) | 265 (41.3) | 50 (41.0) | |
| Yes | 396 (55.7) | 364 (56.8) | 64 (52.5) | |
| NA | 10 (1.4) | 12 (1.9) | 8 (6.6) | |
| T stage (%) | ||||
| 1 | 304 (42.8) | 260 (40.6) | 40 (32.8) | |
| 2 | 382 (53.7) | 305 (47.6) | 57 (46.7) | |
| 3 | 18 (2.5) | 63 (9.8) | 4 (3.3) | |
| 4 | 0 | 11 (1.7) | 0 | |
| NA | 7 (1.0) | 2 (0.3) | 21 (17.2) | |
| N stage (%) | ||||
| 0 | 361 (50.8) | 359 (56.0) | 51 (41.8) | |
| 1 | 188 (26.4) | 185 (28.9) | 37 (30.3) | |
| 2 | 91 (12.8) | 45 (7.0) | 9 (7.4) | |
| 3 | 65 (9.1) | 32 (5.0) | 4 (3.3) | |
| NA | 6 (0.8) | 20 (3.1) | 21 (17.2) | |
| Histology (%) | ||||
| IDC | 640 (90.0) | 408 (63.7) | 97 (79.5) | |
| ILC | 18 (2.5) | 43 (6.7) | 11 (9.0) | |
| Others | 53 (7.5) | 3 (0.5) | 3 (2.5) | |
| NA | 0 | 187 (29.2) | 11 (9.0) | |
| Grade (%) | ||||
| 1 | 5 (0.7) | 48 (7.5) | 27 (22.1) | |
| 2 | 273 (38.4) | 102 (15.9) | 67 (54.9) | |
| 3 | 377 (53.0) | 485 (75.7) | 17 (13.9) | |
| NA | 56 (7.9) | 6 (0.9) | 11 (9.0) | |
| ER status (%) | ||||
| Positive | 402 (56.5) | 481 (75.0) | 104 (85.2) | |
| Negative | 309 (43.5) | 160 (25.0) | 18 (14.8) | |
| PR status (%) | ||||
| Positive | 343 (48.2) | 418 (65.2) | 92 (75.4) | |
| Negative | 367 (51.6) | 223 (34.8) | 30 (24.6) | |
| NA | 1 (0.1) | 0 | 0 | |
| HER2 status (%) | ||||
| Positive | 232 (32.6) | 112 (17.5) | 25 (20.5) | |
| Negative | 479 (67.4) | 529 (82.5) | 95 (77.9) | |
| Equivocal | 0 | 0 | 1 (0.8) | |
| NA | 0 | 0 | 1 (0.8) |